Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic J Kaye

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2014
CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvementAntonio L Amelio, Mohammad Fallahi, Franz X Schaub, et al.
JCI Insight|April 8, 2021
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinomaZirong Chen, Wei Ni, Jian-Liang Li, et al.
JCI Insight|September 1, 2022
Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survivalVinod Vijayakurup, Kyungah Maeng, Hye Seung Lee, et al.
Journal of the National Cancer Institute|December 4, 2014
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancerChunxia Cao, Ruli Gao, Min Zhang, et al.
Oral Oncology|October 14, 2019
MYB-activated models for testing therapeutic agents in adenoid cystic carcinomaYue Jiang, Ruli Gao, Chunxia Cao, et al.
The Journal of Clinical Investigation|April 30, 2019
Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survivalPatrick Kellish, Daniil Shabashvili, Masmudur M Rahman, et al.
The Journal of Clinical Investigation|May 4, 2016
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growthZirong Chen, Jian-Liang Li, Shuibin Lin, et al.
Cell Death Discovery|January 1, 2023
Co-targeting BCL-X<sub>L</sub> and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in miceSajid Khan, Patrick Kellish, Nick Connis, et al.
Science (New York, N.Y.)|May 1, 2004
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyJ Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, et al.
JCI Insight|April 25, 2023
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survivalMaria V Guijarro, Patrick C Kellish, Peter E Dib, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2014
CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvementAntonio L Amelio, Mohammad Fallahi, Franz X Schaub, et al.
JCI Insight|April 8, 2021
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinomaZirong Chen, Wei Ni, Jian-Liang Li, et al.
JCI Insight|September 1, 2022
Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survivalVinod Vijayakurup, Kyungah Maeng, Hye Seung Lee, et al.
Journal of the National Cancer Institute|December 4, 2014
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancerChunxia Cao, Ruli Gao, Min Zhang, et al.
Oral Oncology|October 14, 2019
MYB-activated models for testing therapeutic agents in adenoid cystic carcinomaYue Jiang, Ruli Gao, Chunxia Cao, et al.
The Journal of Clinical Investigation|April 30, 2019
Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survivalPatrick Kellish, Daniil Shabashvili, Masmudur M Rahman, et al.
The Journal of Clinical Investigation|May 4, 2016
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growthZirong Chen, Jian-Liang Li, Shuibin Lin, et al.
Cell Death Discovery|January 1, 2023
Co-targeting BCL-X<sub>L</sub> and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in miceSajid Khan, Patrick Kellish, Nick Connis, et al.
Science (New York, N.Y.)|May 1, 2004
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyJ Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, et al.
JCI Insight|April 25, 2023
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survivalMaria V Guijarro, Patrick C Kellish, Peter E Dib, et al.
Pageof 8